Vogenx Inc VOGX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
Vogenx Appoints Ken Toombs to Board of Directors
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
Vogenx Announces Closing of Initial Public Offering
Vogenx Announces Pricing of Initial Public Offering
Trading Information
- Previous Close Price
- $18.23
- Day Range
- $18.67–19.12
- 52-Week Range
- $12.95–36.97
- Bid/Ask
- $17.72 / $19.69
- Shares Outstanding
- 14.86M
- Market Cap
- $270.81M
- Volume/Avg
- 1,073 / 157,203
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 5
- Website
- https://www.vogenx.com
Valuation
Metric | VOGX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | VOGX |
|---|---|
Quick Ratio | 0.06 |
Current Ratio | 0.44 |
Interest Coverage | — |
Quick Ratio
VOGX
Profitability
Metric | VOGX |
|---|---|
Return on Assets (Normalized) | −162.85% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
VOGX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|n!^GP& | LOCK|<sHdP | $138B | |||
| Moderna Inc MRNA | LOCK|Vb>@rr@ | LOCK|&l | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|lYDY^$Z | LOCK|x%>D | $93B | |||
| argenx SE ADR ARGX | LOCK|D!wJ<VC | LOCK|%$^ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|^<l$bz | LOCK|>^% | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|>P&BP&nj | LOCK|L?>$ | $30B | |||
| Incyte Corp INCY | LOCK|<?J@>^ | LOCK|#$ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|>@n?$^ | LOCK|<z! | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|?^d<N& | LOCK|Shh^? | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|>kW^q@s | LOCK|>c> | $15B |
United States